Oligonucleotide Synthesis Market

The global oligonucleotide synthesis market is projected to reach USD 19.7 billion by 2029 from USD 8.8 billion in 2024, at a CAGR of 17.5% during the forecast period. The major factors driving the growth of this market are the increasing adoption of oligonucleotides in therapeutics for the treatment of many neurological and rare diseases, ongoing funding and investments provided by the government and major players for life science and synthetic biology research and growing awareness about alternate therapies for various diseases.

The players operating in the oligonucleotide synthesis market are Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), LGC Limited (UK), Agilent Technologies, Inc. (US), Kaneka Corporation (Japan), Maravai Lifesciences holdings, Inc. (US), Azenta, Inc. (US), Twist Bioscience Corporation (US) and Genscript Biotech Corporation (US).

To know about the assumptions considered for the study download the pdf brochure

Prominent players in the oligonucleotide therapeutics market are Biogen Inc. (US), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), Astrazeneca (UK), Astellas Pharma Inc. (Japan), Jazz Pharmaceuticals Plc (Ireland), Nippon Shinyaku, Co. Ltd. (Japan), Ionis Pharmaceuticals, Inc. (US) and Novartis AG (Switzerland).

DANAHER CORPORATION (US)

Danaher is one of the key players in the oligonucleotide synthesis market. The company through its two major subsidiary Integrated DNA Technologies (IDT) and Cytiva offers various products such as predesigned and custom oligonucelotide probes, primers, as well as therapeutic oligonucleotides such as ASOs, apart from this the company provides reagents, consumables and equipments such as synthesizers for oligonucelotide synthesis. Geographically, the company operates in more than 50 countries across North America, Asia Pacific, Europe, the Middle East, and Africa. IDT and Cytiva uses organic strategies such as expansions and partnerships as their key growth strategies. In 2023, Integrated DNA Technologies (IDT) opened its therapeutic oligonucleotide manufacturing facility in Coralville, Iowa. This facility will produce reagents for cGMP cell & gene therapy, including single-guide RNAs and HDR donor oligos. In 2022, Cytiva partnered with General Biol (Anhui) Co., Ltd. a company from China to provide an integrated FlexFactory platform featuring the OligoProcess nucleic acid synthesis system, ÄKTAprocess purification system, Uniflux tangential flow filtration system, and other advanced technologies. This setup will allow General Biol (Anhui) Co., Ltd. to expand its oligonucleotide CDMO business.

THERMO FISHER SCIENTIFIC, INC. (US)

Thermo Fisher Scientific (US) held the second-largest share in the oligonucleotide synthesis market in 2023. This significant share is due to the pressnec of a strong product portfolio, including custom and predesigned primers, probes, DNA, and RNA oligos, as well as reagents and consumables. The company undertakes various organic and inorganic strategies to strengthen its position in the market. For instance, in 2021, Thermo Fisher Scientific entered in a strategic collaboration with the University of Sheffield aimed at developing workflows for the characterization and monitoring of complex oligonucleotide and mRNA products utilizing various technologies from Thermo Fisher and the research expertise of the University of Sheffield. The company also has a strong geographic presence and operates in more than 50 countries across the North America, Europe, Asia Pacific and the Latim America regions.

BIOGEN, INC. (US)

Biogen held a leading position in 2023 in the oligonucleotide-based drugs market. Recent FDA accelerated approval for QALSODY (Tofersen) for the treatment of amyotrophic lateral sclerosis (ALS) in adults and a growing adoption its blockbuster drug, Spinzara, an oligonucleotide-based drug offered by the company since 2016 are factors supporting its leading position in the market. The company has its oligonucleotide synthesis manufacturing (OSM) facility in North Carolina, which is utilized for manufacturing antisense oligonucleotide drugs like SPINRAZA and other antisense oligonucleotide drug candidates, which are currently in the pipeline. The company focuses on various strategies such as expansions and collaborations to strengthen its position in the market. For instance, in 2022, Biogen and Ionis collaborated to develop and commercialize BIIB115, which is an investigational antisense oligonucleotide (ASO) in development for spinal muscular atrophy (SMA).

Related Reports:

Oligonucleotide Synthesis Market by Product (Drugs (ASO, siRNA), Synthesized Oligo (Primer), Reagents, Equipment), Type (Custom, Predesigned), Application (Therapeutic (Neurology, Rare), Research (PCR, Sequencing), Diagnostics) - Global Forecast to 2029

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]